Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

December 12, 2019

Fully-human BCMA CAR-T clinical results to treat relapsed/refractory multiple myeloma co-developed by IASO BIO and Innovent presented at 2019 ASH Annual Meeting

IASO Biotherapeutics, a clinical-stage biotechnology company advancing the development of innovative therapies for cancer, had the latest clinical data presented on their potential best-in-class therapy at the “Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma” session during the prestigious 61st Annual American Society of Hematology (ASH) Meeting & Exposition, December 7-10 in Orlando.

Fully-human BCMA CAR-T clinical results to treat relapsed/refractory multiple myeloma co-developed by IASO BIO and Innovent presented at 2019 ASH Annual Meeting